Single-cell sequencing of roughly 80,000 astrocytes from inflamed mouse brains has shattered the old idea that neuroinflammation produces just two flavors of reactive astrocyte. Instead, inflammation drives multiple distinct astrocyte subtypes, each with its own gene-expression profile and, in many cases, its own preferred brain region. This granular picture, anchored by a landmark 2021 study in Nature Neuroscience, has reshaped how researchers think about the role of astrocytes in diseases from Alzheimer’s to multiple sclerosis and even normal aging.
Why the A1/A2 Framework Fell Short
For several years, the field relied on a tidy binary: A1 astrocytes were “neurotoxic,” triggered by inflammation, and A2 astrocytes were “neuroprotective,” triggered by injury such as ischemia.1PubMed Central. Astrocytes: a double-edged sword in neurodegenerative diseases The labels were borrowed from the M1/M2 macrophage concept and had the same appeal: simple, memorable, easy to slot into grant applications. But as single-cell technologies matured, the binary started crumbling. Researchers found astrocytes that expressed hallmarks of both A1 and A2 states simultaneously, cells that fit neither category, and inflammatory profiles that varied depending on what brain region the astrocyte sat in. The field now treats A1 and A2 as useful historical shorthand rather than literal cell types.
The clearest evidence for this complexity came from a study that profiled about 80,000 individual astrocytes from the mouse brain at single-cell resolution. The authors showed that inflammation triggers a widespread response, but within that response, distinct subtypes of astrocytes undergo separate inflammatory transitions, each with a defined transcriptomic profile.2PubMed. Neuroinflammatory astrocyte subtypes in the mouse brain Rather than a single “on” switch flipping astrocytes to one reactive state, the picture looks more like a dashboard with many dials turning independently.
How Microglia Kick Off the Process
Astrocytes do not typically inflame themselves. The opening signal usually comes from microglia, the brain’s resident immune cells. When microglia detect damage or infection, they release a cocktail of three signaling molecules: interleukin-1 alpha (IL-1α), tumor necrosis factor (TNF), and complement component C1q. Together, these three molecules are both necessary and sufficient to push astrocytes into a neurotoxic reactive state.3PubMed Central. Neurotoxic reactive astrocytes are induced by activated microglia This was a pivotal finding because it placed microglia upstream in the causal chain: block the microglial signals, and you can in principle prevent the downstream astrocyte toxicity.
Once flipped into this reactive state, astrocytes stop doing many of the things healthy astrocytes are supposed to do. They downregulate genes involved in neuronal survival, synapse support, and blood-brain barrier maintenance. In their place, they begin producing neurotoxic factors, complement proteins such as C3, and chemokines like CXCL10 that recruit more immune cells into the brain.4PubMed Central. Roles of neuropathology-associated reactive astrocytes: a systematic review The result is a feed-forward loop: microglia activate astrocytes, astrocytes recruit more immune cells, and the inflammation deepens.
NF-κB Sits at the Center
If you trace the signaling pathways inside inflammatory astrocytes, one transcription factor keeps showing up: NF-κB. This protein complex acts as a master switch for inflammatory gene expression in many cell types, and astrocytes are no exception. In mouse models exposed to both manganese and a neurotoxic challenge, astrocyte-specific knockout of a key NF-κB activator reduced the inflammatory response in glia, demonstrating that NF-κB signaling specifically within astrocytes amplifies neuroinflammation.5PubMed Central. NF-κB Signaling in Astrocytes Modulates Brain Inflammation and Neuronal Injury Following Sequential Exposure to Manganese and MPTP During Development and Aging
Work in a Drosophila model of neurodegeneration reinforced this: when an NF-κB-family transcription factor called Relish was blocked in glial cells, neurodegeneration slowed.6PubMed Central. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons There is also evidence that the pathway can be dialed down rather than simply switched off. In human multiple sclerosis brain tissue, interleukin-9 was found to contribute to shifting astrocytes from an inflammatory toward an anti-inflammatory profile by suppressing NF-κB activation and inhibiting production of GM-CSF, a pro-inflammatory growth factor.7PubMed Central. Interleukin-9 Regulates NF-kB-Mediated Activation of Astrocytes in Multiple Sclerosis Brain So NF-κB is not a one-way street; endogenous signals exist that can push it back in the protective direction.
Complement C3 and Lipocalin-2 as Key Markers
Two molecules have become especially useful for identifying and studying neurotoxic reactive astrocytes in mouse models. The first is complement component C3. In the original A1 framework, C3 was the go-to marker for neurotoxic astrocytes, and it remains widely used even as the field moves past strict A1/A2 labels. Experiments in mice that underwent abdominal surgery showed that the procedure induced neurotoxic reactive astrocytes with elevated C3 in the hippocampus, and that knocking down C3 with a viral vector prevented microglia from engulfing synapses, protecting the animals from cognitive decline.8Journal of Neuroimmune Pharmacology. Complement C3 From Astrocytes Plays Significant Roles in Sustained Activation of Microglia and Cognitive Dysfunctions Triggered by Systemic Inflammation After Laparotomy in Adult Male Mice That study nicely illustrates how astrocyte-derived C3 feeds back to microglia, creating the loop described earlier.
The second molecule is lipocalin-2 (Lcn-2), a secretory protein produced mainly by activated astrocytes. Lcn-2 amplifies inflammation through NF-κB and JAK-STAT signaling, making it both a biomarker and a functional player in neuroinflammatory astrocyte activation.9PubMed Central. The interaction of lipocalin-2 and astrocytes in neuroinflammation: mechanisms and therapeutic application In stroke models, knocking out Lcn-2 shrank the area of brain damage and improved neurological and cognitive outcomes.10Journal of Neuroinflammation. Lipocalin-2-mediated astrocyte pyroptosis promotes neuroinflammatory injury via NLRP3 inflammasome activation in cerebral ischemia/reperfusion injury Beyond its role in disease, Lcn-2 has been leveraged to build genetic tools that label reactive astrocytes specifically, making it possible to track and manipulate these cells in living mice.
Not All Brain Regions Respond the Same Way
One of the most striking findings from the ~80,000-cell dataset is that reactive astrocyte subtypes map onto specific brain regions. Using spatial transcriptomics and in situ hybridization, the researchers attributed key inflammatory astrocyte sub-states to particular anatomical locations.11PubMed. Neuroinflammatory astrocyte subtypes in the mouse brain In other words, the same inflammatory trigger can produce different reactive astrocyte gene-expression profiles depending on whether the cell sits in the cortex, hippocampus, or another region.
This regional heterogeneity has been confirmed in disease-specific contexts. In a mouse model of experimental autoimmune encephalomyelitis (EAE), which mimics multiple sclerosis, spinal cord astrocytes showed a pronounced neuroinflammatory and neurotoxic signature during acute disease, while astrocyte responses in other regions differed. As the disease moved into its chronic phase, the spinal cord astrocytes shifted toward a more proliferative profile, possibly contributing to scar formation and early tissue repair.12Glia. Regionally diverse astrocyte subtypes and their heterogeneous response to EAE Astrocytes also participate more broadly in MS-related inflammation through cytokine and chemokine production, oxidative stress regulation, and maintenance of blood-brain barrier integrity.13PubMed Central. The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis
Spatial transcriptomics around amyloid plaques in Alzheimer’s mouse models reveals a similar pattern. While the microglial response to plaques looks fairly consistent across brain regions, the astrocytic response is more heterogeneous. As microglial density around a plaque increases, nearby astrocytes adopt a more neurotoxic phenotype and begin altering neuronal signaling, boosting inhibitory GABAergic tone while dampening excitatory glutamatergic activity in the hippocampus.14PubMed. Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomics The implication is that astrocyte reactivity depends not just on the type of insult but on the local cellular neighborhood.
Disease-Associated Astrocytes in Alzheimer’s Models
Single-nucleus RNA sequencing in Alzheimer’s mouse models has revealed a specific population now called disease-associated astrocytes (DAAs). These cells appear at early disease stages and grow more abundant as the disease progresses.15PubMed Central. Disease-associated astrocytes in Alzheimer’s disease and aging Intriguingly, similar astrocytes also turn up in aged wild-type mice with no engineered pathology and in aging human brains, suggesting that the DAA profile is tied to aging itself, not solely to amyloid or tau accumulation.
More recent work has subdivided the reactive astrocyte landscape in Alzheimer’s further. A study mapping astrocyte changes across different brain regions and disease stages in human tissue identified at least two distinct reactive subclusters enriched in stress-response and extracellular-matrix genes, yet differing in other markers. One subcluster expressed complement C3 and oxidative-stress-related genes, while the other leaned toward synaptic-organization genes, suggesting different functional roles even within the “reactive” umbrella.16Nature Neuroscience. Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease
Aging Shifts the Baseline
You do not need a disease to see astrocyte inflammation in the brain. Normal aging in mice is enough to push astrocytes toward a reactive phenotype resembling the neurotoxic A1-like state.17Proceedings of the National Academy of Sciences. Normal aging induces A1-like astrocyte reactivity This means that by the time an older mouse (or person) encounters a brain injury or neurodegenerative insult, the astrocyte population is already primed for an exaggerated inflammatory response.
That priming has measurable consequences. After traumatic brain injury, aged mice show a progressive worsening of astrogliosis over time, with disproportionate changes in genes linked to reactive astrocytes, inflammation, complement signaling, and synaptic support compared to young mice with the same injury.18Journal of Neuroinflammation. Effects of advanced age upon astrocyte-specific responses to acute traumatic brain injury in mice The authors describe this as a potentially maladaptive phenotype, one that may help explain why older brains are more fragile and recover more slowly after trauma.
Metabolic Reprogramming Under Inflammation
Reactive astrocytes do not just change which genes they express; they also rewire their metabolism. Under inflammatory conditions, astrocytes ramp up glycolysis and fatty acid oxidation to meet increased energy demands. In the short term, this metabolic shift can be protective, supplying fuel to nearby neurons and supporting barrier repair. But when the inflammation becomes chronic, the same metabolic reprogramming can backfire, producing reactive oxygen species and sustaining the inflammatory environment.19PubMed Central. Metabolic Reprogramming of Astrocytes in Pathological Conditions: Implications for Neurodegenerative Diseases This dual nature is a recurring theme: the acute response is often helpful, but when it persists, it tips into damage.
Blood-Brain Barrier Breakdown
Astrocytes are physically woven into the blood-brain barrier, extending foot-like projections that wrap around blood vessels. When astrocytes become reactive, they can actively compromise the barrier they normally maintain. In mouse models of intracerebral hemorrhage, activation of a toll-like receptor called TLR2 on astrocytes triggered production of matrix metalloproteinase-9 (MMP9), an enzyme that degrades the structural proteins holding the barrier together. Mice lacking TLR2 had less barrier damage after hemorrhage.20PubMed Central. TLR2-induced astrocyte MMP9 activation compromises the blood brain barrier and exacerbates intracerebral hemorrhage in animal models A leaky barrier lets blood-borne immune cells and inflammatory molecules flood into the brain tissue, amplifying neuroinflammation further.
Therapeutic Angles
The expanding catalog of neuroinflammatory astrocyte subtypes has opened several therapeutic avenues in mouse models. One promising target is the Nrf2 pathway, a cellular defense system against oxidative and inflammatory stress. In Alzheimer’s model mice, boosting Nrf2 activity with a small molecule called ALGERNON2 counteracted NF-κB signaling, suppressed the induction of neurotoxic reactive astrocytes, and rescued cognitive deficits.21PubMed Central. Astrocyte-targeting therapy rescues cognitive impairment caused by neuroinflammation via the Nrf2 pathway The Nrf2-treated astrocytes showed reduced expression of type I interferon and antigen-presentation genes, two hallmarks of the inflammatory reactive state.
Other strategies target the downstream markers directly. Maraviroc, a drug originally developed as an HIV entry inhibitor, reduced levels of C3-positive neurotoxic astrocytes in the cortex of mice after traumatic brain injury.22PubMed Central. Maraviroc promotes recovery from traumatic brain injury in mice by suppression of neuroinflammation and activation of neurotoxic reactive astrocytes And semaglutide, a GLP-1 receptor agonist known primarily as a diabetes and obesity drug, was shown to inhibit C3-positive reactive astrocytes in the striatum of Parkinson’s disease model mice. When combined with neural stem cell transplantation, semaglutide improved the survival and differentiation of the transplanted cells, partly by clearing the hostile astrocyte environment.23Advanced Science. The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson’s Disease Mice
Each of these interventions works at a different point in the cascade. Nrf2 activation blocks the transcriptional programs that turn astrocytes reactive. Maraviroc intervenes at the chemokine-receptor level. Semaglutide appears to dampen the reactive state through metabolic and anti-inflammatory effects on GLP-1 receptor-expressing cells. None has been tested in humans for this specific purpose, but the variety of entry points reflects how well the subtype landscape is now understood at the molecular level.
From Mouse to Human
A natural question is how well any of this translates. Cross-species comparisons have been mixed. An integrated atlas of astrocyte gene expression across mouse models and human patients with Alzheimer’s disease found only 35 genes consistently upregulated in both species, and in multiple sclerosis the overlap was even smaller, just four genes.24bioRxiv. Integrated Cross-Disease Atlas of Human And Mouse Astrocytes Reveals Heterogeneity and Conservation of Astrocyte Subtypes in Neurodegeneration Among those shared genes in Alzheimer’s were factors involved in microglia communication, neuroprotection, and astrocyte-driven inflammation. But the species-specific differences were striking: mouse astrocytes mounted a strong interferon response, while human astrocytes leaned more heavily into synaptic-organization genes. The implication is that mouse models capture part of the human astrocyte response but miss substantial biology.
Studies using induced pluripotent stem cells to generate human astrocytes in culture have added another layer. When researchers derived white-matter-like and grey-matter-like human astrocytes and compared them to mouse equivalents, the overall affected pathways were similar, but the human white-matter astrocytes engaged disease mechanisms not seen in the mouse cells.25PubMed Central. Human and mouse iPSC-derived astrocyte subtypes reveal vulnerability in Vanishing White Matter These gaps matter. Drug candidates that look promising against mouse reactive astrocytes may fail in humans if they target a pathway that is species-specific.
Gut Microbiome Connections
One of the more unexpected threads in astrocyte biology involves the gut. In EAE mouse models, microbial metabolites including short-chain fatty acids and tryptophan derivatives have been shown to modulate the immune system, mainly by promoting regulatory T cells that dial down inflammation.26European Journal of Immunology. The role of the gut microbiota and microbial metabolites in neuroinflammation These metabolites can reach the brain and interact with astrocytes, influencing whether they adopt a more inflammatory or more protective profile. The research is still in early stages, but it raises the possibility that the state of the gut microbiome, shaped by diet and other factors, helps set the tone for astrocyte reactivity during neuroinflammatory disease.
Genetic Tools for Tracking Reactive Astrocytes
Studying astrocyte subtypes in living animals requires tools that can distinguish reactive astrocytes from their quiescent neighbors. A recent advance uses the Lcn-2 gene promoter fused to a tamoxifen-inducible Cre recombinase system. Because Lcn-2 is sharply upregulated in reactive astrocytes but low in healthy ones, this system labels reactive astrocytes only when inflammation is present and the researcher administers tamoxifen. In validation experiments, mice injected with a reporter virus and then treated with an inflammatory stimulus showed strong reporter expression in reactive astrocytes, while saline-treated controls showed minimal signal beyond the injection site.27Cell Reports Methods. An inducible genetic tool for the targeting and manipulation of reactive astrocytes This kind of tool is what enables the next generation of experiments, selectively deleting a gene or expressing a therapeutic protein in reactive astrocytes while leaving healthy astrocytes untouched. It also brings the field closer to testing whether eliminating or reprogramming specific subtypes changes disease outcomes, moving beyond correlation toward causation.